$2850 | Single User
$3255 | Five User License
$4065 | Enterprise License

Malaysia Intravenous Immunoglobulin (IVIG) Market by Product Types (IgG, IgA, IgM, IgE and IgD), Application (Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy, Immunodeficiency Diseases, Myasthenia Gravis, Multifocal Motor Neuropathy, Primary Immune Thrombocytopenic Purpura, Inflammatory Myopathies, Specific Antibody Deficiency, Guillain-Barré Syndrome, Kawasaki Disease,
[Report Updated: 24-05-2017]

Published by Allied Market Research: 24 May 2017 | 103575 | In Stock

Introduction

CHAPTER 1 INTRODUCTION

1.1. REPORT DESCRIPTION

1.2. KEY BENEFITS FOR STAKEHOLDERS

1.3. KEY MARKET SEGMENTS

1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research

1.4.2. Primary research

1.4.3. Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE

3.2. OVERVIEW OF IVIG

3.2.1. Patented products

3.3. EPIDEMIOLOGY AND ECONOMIC BURDEN OF CHRONIC CONDITIONS

3.4. COST OF SIDE EFFECTS DUE TO IVIG TREATMENTS

3.5. KEY FINDINGS

3.5.1. Top factors impacting Malaysia IVIG market

3.5.2. Top investment pockets

3.6. PORTERS FIVE FORCES ANALYSIS

3.7. VALUE CHAIN ANALYSIS

3.7.1. Primary activities

3.7.2. Support activities

3.8. PRODUCT SCENARIO IN IVIG MARKET

3.9. GOVERNMENT REGULATIONS AND REIMBURSEMENTS

3.10. COMPONENT ANALYSIS OF IMMUNOGLOBULIN G (IGG)

3.10.1. IgG1

3.10.2. IgG2

3.10.3. IgG3

3.10.4. IgG4

3.11. MARKET DYNAMICS

3.11.1. Drivers

3.11.1.1. Rise in number of immunodeficiency diseases

3.11.1.2. Increase in adoption of IVIG

3.11.1.3. Increase in number of people with bleeding disorders

3.11.1.4. Rise in aging population

3.11.2. Restraints

3.11.2.1. Stringent regulations

3.11.2.2. High cost of IVIG therapy

3.11.3. Opportunities

3.11.3.1. Untapped potential of Malaysia as an emerging economy

3.11.3.2. Development of cost-effective therapeutics through large-scale production

CHAPTER 4 MALAYSIA IVIG MARKET, BY APPLICATION

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. HYPOGAMMAGLOBULINEMIA

4.2.1. Market size and forecast

4.3. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIPD)

4.3.1. Market size and forecast

4.4. IMMUNODEFICIENCY DISEASES (ID)

4.4.1. Market size and forecast

4.5. MYASTHENIA GRAVIS (MG)

4.5.1. Market size and forecast

4.6. MULTIFOCAL MOTOR NEUROPATHY (MMN)

4.6.1. Market size and forecast

4.7. PRIMARY IMMUNE THROMBOCYTOPENIC PURPURA (PITP)

4.7.1. Market size and forecast

4.8. INFLAMMATORY MYOPATHIES (IM)

4.8.1. Market size and forecast

4.9. SPECIFIC ANTIBODY DEFICIENCY (SAD)

4.9.1. Market size and forecast

4.10. GUILLAIN-BARR SYNDROME (GBS)

4.10.1. Market size and forecast

4.11. KAWASAKI DISEASE (KD)

4.11.1. Market size and forecast

4.12. SECONDARY IMMUNE DEFICIENCY (SID)

4.12.1. Market size and forecast

4.13. OTHERS

4.13.1. Market size and forecast

CHAPTER 5 MALAYSIA IVIG MARKET, BY PRODUCT

5.1. OVERVIEW

5.2. IGG

5.2.1. Key market trends

5.2.2. Clinical interpretations

5.3. IGA

5.3.1. Key market trends

5.3.2. Clinical interpretations

5.4. IGM

5.4.1. Key market trends

5.4.2. Clinical interpretations

5.5. IGE

5.5.1. Key market trends

5.5.2. Clinical interpretations

5.6. IGD

5.6.1. Key market trends

5.6.2. Clinical interpretations

CHAPTER 6 MALAYSIA IVIG MARKET, BY MODE OF DELIVERY

6.1. OVERVIEW

6.1.1. Market size and forecast

6.2. INTRAVENOUS MODE OF DELIVERY

6.2.1. Market size and forecast

6.3. SUBCUTANEOUS MODE OF DELIVERY

6.3.1. Market size and forecast

6.4. INTRAMUSCULAR MODE OF DELIVERY

6.4.1. Market size and forecast

CHAPTER 7 MALAYSIA IVIG MARKET, BY CONCENTRATION

7.1. OVERVIEW

7.1.1. Market size and forecast

7.2. 5% CONCENTRATION

7.2.1. Market size and forecast

7.3. 10% CONCENTRATION

7.3.1. Market size and forecast

7.4. OTHER CONCENTRATIONS

7.4.1. Market size and forecast

CHAPTER 8 COMPANY PROFILES

8.1. BAXTER INTERNATIONAL INC.

8.1.1. Company overview

8.1.2. Company snapshot

8.1.3. Operating business segments

8.1.4. Product portfolio

8.1.5. Business performance

8.2. BAYER AG

8.2.1. Company overview

8.2.2. Company snapshot

8.2.3. Operating business segments

8.2.4. Product portfolio

8.2.5. Business performance

8.3. BIOTEST AG

8.3.1. Company overview

8.3.2. Company snapshot

8.3.3. Operating business segments

8.3.4. Product portfolio

8.3.5. Business performance

8.3.6. Key strategic moves and developments

8.4. CSL LTD.

8.4.1. Company overview

8.4.2. Company snapshot

8.4.3. Operating business segments

8.4.4. Product portfolio

8.4.5. Business performance

8.4.6. Key strategic moves and developments

8.5. GREEN CROSS CORPORATION

8.5.1. Company overview

8.5.2. Company snapshot

8.5.3. Operating business segments

8.5.4. Product portfolio

8.5.5. Business performance

8.5.6. Key strategic moves and developments

8.6. GRIFOLS S.A.

8.6.1. Company overview

8.6.2. Company snapshot

8.6.3. Operating business segments

8.6.4. Product portfolio

8.6.5. Business performance

8.6.6. Key strategic moves and developments

8.7. JOHNSON & JOHNSON

8.7.1. Company overview

8.7.2. Company snapshot

8.7.3. Operating business segments

8.7.4. Product portfolio

8.7.5. Business performance

8.8. KEDRION S.P.A.

8.8.1. Company overview

8.8.2. Company snapshot

8.8.3. Operating business segments

8.8.4. Product portfolio

8.8.5. Business performance

8.8.6. Key strategic moves and developments

8.9. OCTAPHARMA AG

8.9.1. Company overview

8.9.2. Company snapshot

8.9.3. Operating business segments

8.9.4. Product portfolio

8.9.5. Business performance

8.10. SHIRE PLC

8.10.1. Company overview

8.10.2. Company snapshot

8.10.3. Product portfolio

8.10.4. Business performance

8.10.5. Key strategic moves and developments

Table of Contents
for Malaysia Intravenous Immunoglobulin (IVIG) Market by Product Types (IgG, IgA, IgM, IgE and IgD), Application (Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy, Immunodeficiency Diseases, Myasthenia Gravis, Multifocal Motor Neuropathy, Primary Immune Thrombocytopenic Purpura, Inflammatory Myopathies, Specific Antibody Deficiency, Guillain-Barré Syndrome, Kawasaki Disease, [Report Updated: 24-05-2017]

  • LIST OF TABLES

    TABLE 1. IGG SUBCLASS

    TABLE 2. FREQUENCY (%) OF DECREASED IGG SUBCLASS CONCENTRATION IN ADULTS

    TABLE 3. DISEASES ASSOCIATED WITH IGG SUBCLASS DEFICIENCY

    TABLE 4. MALAYSIA IVIG MARKET, BY APPLICATION, 2014-2022 ($THOUSAND)

    TABLE 5. MALAYSIA IVIG MARKET, BY APPLICATION, 2014-2022 (KILOGRAM)

    TABLE 6. COMMON MEDICATION FOR THE HYPOGAMMAGLOBULINEMIA ASSOCIATED WITH RECURRENT BACTERIAL INFECTIONS

    TABLE 7. MALAYSIA IVIG MARKET FOR HYPOGAMMAGLOBULINEMIA APPLICATION, 2014-2022 ($THOUSAND AND KILOGRAM)

    TABLE 8. MALAYSIA IVIG MARKET FOR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY APPLICATION, 2014-2022 ($THOUSAND & KILOGRAM)

    TABLE 9. PRINCIPLE OF IVIG THERAPY IN IMMUNODEFICIENCY

    TABLE 10. MALAYSIA IVIG MARKET FOR PRIMARY IMMUNODEFICIENCY DISEASE APPLICATION, 2014-2022 ($THOUSAND & KILOGRAM)

    TABLE 11. MALAYSIA IVIG MARKET FOR MYASTHENIA GRAVIS APPLICATION, 2014-2022 ($THOUSAND AND KILOGRAM)

    TABLE 12. MALAYSIA IVIG MARKET FOR MULTIFOCAL MOTOR NEUROPATHY APPLICATION, 2014-2022 ($THOUSAND & KILOGRAM)

    TABLE 13. MALAYSIA IVIG MARKET FOR PRIMARY IMMUNE THROMBOCYTOPENIC PURPURA APPLICATION, 2014-2022 ($THOUSAND & KILOGRAM)

    TABLE 14. MALAYSIA IVIG MARKET FOR INFLAMMATORY MYOPATHY APPLICATION, 2014-2022 ($THOUSAND & KILOGRAM)

    TABLE 15. MALAYSIA IVIG MARKET FOR SPECIFIC ANTIBODY DEFICIENCY APPLICATION, 2014-2022 ($THOUSAND & KILOGRAM)

    TABLE 16. MALAYSIA IVIG MARKET FOR GUILLAIN-BARR SYNDROME APPLICATION, 2014-2022 ($THOUSAND & KILOGRAM)

    TABLE 17. MALAYSIA IVIG MARKET FOR KAWASAKI DISEASE APPLICATION, 2014-2022 ($THOUSAND & KILOGRAM)

    TABLE 18. IVIG MARKET FOR SECONDARY IMMUNODEFICIENCY APPLICATION, 2014-2022 ($THOUSAND & KILOGRAM)

    TABLE 19. MALAYSIA IVIG MARKET FOR OTHER APPLICATIONS, 2014-2022 ($THOUSAND & KILOGRAM)

    TABLE 20. MALAYSIA IVIG MARKET, BY MODE OF DELIVERY, 2014-2022 ($THOUSAND)

    TABLE 21. MALAYSIA IVIG MARKET, BY MODE OF DELIVERY, 2014-2022 (KILOGRAM)

    TABLE 22. MALAYSIA IVIG MARKET FOR INTRAVENOUS MODE OF DELIVERY, 2014-2022 ($THOUSAND & KILOGRAM)

    TABLE 23. MALAYSIA IVIG MARKET FOR SUBCUTANEOUS MODE OF DELIVERY, 2014-2022 ($THOUSAND & KILOGRAM)

    TABLE 24. MALAYSIA IVIG MARKET FOR INTRAMUSCULAR MODE OF DELIVERY, 2014-2022 ($THOUSAND & KILOGRAM)

    TABLE 25. MALAYSIA IVIG MARKET, BY CONCENTRATION, 2014-2022 ($THOUSAND)

    TABLE 26. MALAYSIA IVIG MARKET, BY CONCENTRATION, 2014-2022 (KILOGRAM)

    TABLE 27. MALAYSIA IVIG MARKET FOR 5% CONCENTRATION, 2014-2022 ($THOUSAND & KILOGRAM)

    TABLE 28. MALAYSIA IVIG MARKET FOR 10% CONCENTRATION, 2014-2022 ($THOUSAND & KILOGRAM)

    TABLE 29. MALAYSIA IVIG MARKET FOR OTHER CONCENTRATIONS, 2014-2022 ($THOUSAND & KILOGRAM)

    TABLE 30. BAXTER: COMPANY SNAPSHOT

    TABLE 31. BAXTER: OPERATING SEGMENTS

    TABLE 32. BAXTER: PRODUCT PORTFOLIO

    TABLE 33. BAYER: COMPANY SNAPSHOT

    TABLE 34. BAYER: OPERATING SEGMENTS

    TABLE 35. BAYER: PRODUCT PORTFOLIO

    TABLE 36. BIOTEST: COMPANY SNAPSHOT

    TABLE 37. BIOTEST: OPERATING SEGMENTS

    TABLE 38. BIOTEST: PRODUCT PORTFOLIO

    TABLE 39. CSL: COMPANY SNAPSHOT

    TABLE 40. CSL: OPERATING SEGMENTS

    TABLE 41. CSL: PRODUCT PORTFOLIO

    TABLE 42. GREEN CROSS: COMPANY SNAPSHOT

    TABLE 43. GREEN CROSS: OPERATING SEGMENTS

    TABLE 44. GREEN CROSS: PRODUCT PORTFOLIO

    TABLE 45. GRIFOLS: COMPANY SNAPSHOT

    TABLE 46. GRIFOLS: OPERATING SEGMENTS

    TABLE 47. GRIFOLS: PRODUCT PORTFOLIO

    TABLE 48. J&J: COMPANY SNAPSHOT

    TABLE 49. J&J: OPERATING SEGMENTS

    TABLE 50. J&J: PRODUCT PORTFOLIO

    TABLE 51. KEDRION: COMPANY SNAPSHOT

    TABLE 52. KEDRION: OPERATING SEGMENTS

    TABLE 53. KEDRION: PRODUCT PORTFOLIO

    TABLE 54. OCTAPHARMA: COMPANY SNAPSHOT

    TABLE 55. OCTAPHARMA: PRODUCTION AREAS

    TABLE 56. OCTAPHARMA: PRODUCT PORTFOLIO

    TABLE 57. SHIRE: COMPANY SNAPSHOT

    TABLE 58. SHIRE: PRODUCT PORTFOLIO

    LIST OF FIGURES

    FIGURE 1. MARKET SEGMENTATION

    FIGURE 2. PERCENTAGE SHARE OF COST ASSOCIATED WITH SIDE EFFECTS INDUCED BY IVIG THERAPY

    FIGURE 3. TOP FACTORS IMPACTING MALAYSIA IVIG MARKET (2015-2021)

    FIGURE 4. TOP INVESTMENT POCKETS

    FIGURE 5. BARGAINING POWER OF BUYERS

    FIGURE 6. BARGAINING POWER OF SUPPLIERS

    FIGURE 7. THREAT OF NEW ENTRANTS

    FIGURE 8. THREAT OF SUBSTITUTION

    FIGURE 9. COMPETITIVE RIVALRY

    FIGURE 10. VALUE CHAIN ANALYSIS OF MALAYSIA IVIG MARKET

    FIGURE 11. BAXTER: NET SALES, 2014-2016 ($MILLION)

    FIGURE 12. BAXTER: REVENUE BY PRODUCT, 2016 (%)

    FIGURE 13. BAXTER: REVENUE BY GEOGRAPHY, 2016 (%)

    FIGURE 14. BAYER: NET SALES, 2014-2016 ($MILLION)

    FIGURE 15. BAYER: REVENUE BY GEOGRAPHY, 2016 (%)

    FIGURE 16. BIOTEST: NET SALES, 2014-2016 ($MILLION)

    FIGURE 17. BIOTEST: REVENUE BY SEGMENT, 2016 (%)

    FIGURE 18. BIOTEST: REVENUE BY GEOGRAPHY, 2016 (%)

    FIGURE 19. CSL: NET SALES, 2014-2016 ($MILLION)

    FIGURE 20. CSL: REVENUE BY PRODUCT, 2016 (%)

    FIGURE 21. CSL: REVENUE BY GEOGRAPHY, 2016 (%)

    FIGURE 22. GREEN CROSS: NET SALES, 2014-2016 ($MILLION)

    FIGURE 23. GREEN CROSS: REVENUE BY SEGMENT, 2016 (%)

    FIGURE 24. GREEN CROSS: REVENUE BY GEOGRAPHY, 2016 (%)

    FIGURE 25. GRIFOLS: NET SALES, 2014-2016 ($MILLION)

    FIGURE 26. GRIFOLS: REVENUE BY SEGMENT, 2016 (%)

    FIGURE 27. GRIFOLS: REVENUE BY GEOGRAPHY, 2016 (%)

    FIGURE 28. J&J: NET SALES, 2014-2016 ($MILLION)

    FIGURE 29. J&J: REVENUE BY SEGMENT, 2016 (%)

    FIGURE 30. J&J: REVENUE BY GEOGRAPHY, 2016 (%)

    FIGURE 31. KEDRION: NET SALES, 2014-2016 ($MILLION)

    FIGURE 32. OCTAPHARMA: NET SALES, 2014-2016 ($MILLION)

    FIGURE 33. SHIRE: NET SALES, 2014-2016 ($MILLION)

    FIGURE 34. SHIRE: REVENUE BY GEOGRAPHY, 2016 (%)

Additional Details

Publisher

Allied Market Research

Publisher Information

Reference

103575 | LI 172281

Number of Pages

164

Report Format

PDF

Allied Market Research Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Chemical Company of Malaysia Berhad (CCM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
SummaryChemical Company of Malaysia Berhad (CCM) is a holding company which offers products and serv...
29 Jul 2016 by Global Data USD $250 More Info
Medical Device Market in Malaysia to 2020 - Market Size, Development, and Forecasts
The report Medical Device Market in Malaysia to 2020 - Market Size, Development, and Forecasts offer...
22 Jul 2016 by Global Research and Data Services GRDS USD $540 More Info
Dksh Holdings (Malaysia) Berhad (DKSH) - Financial and Strategic SWOT Analysis Review
SummaryDKSH Holdings (Malaysia) Berhad (DKSH) formerly Diethelm Holdings (Malaysia), a subsidiary of...
11 Jul 2016 by Global Data USD $300 More Info
Chemical Company of Malaysia Berhad (CCM) - Financial and Strategic SWOT Analysis Review
Chemical Company of Malaysia Berhad (CCM) - Financial and Strategic SWOT Analysis Review provides yo...
28 Jun 2016 by Global Data USD $125 More Info
Dksh Holdings (Malaysia) Berhad (DKSH) - Financial and Strategic SWOT Analysis Review
SummaryDKSH Holdings (Malaysia) Berhad (DKSH) formerly Diethelm Holdings (Malaysia), a subsidiary of...
15 Apr 2016 by Global Data USD $300 More Info
Chemical Company of Malaysia Berhad (CCM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
SummaryChemical Company of Malaysia Berhad (CCM) is a holding company. It offers products and servic...
12 Apr 2016 by Global Data USD $250 More Info
Chemical Company of Malaysia Berhad (CCM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
SummaryChemical Company of Malaysia Berhad (CCM) is a holding company. It offers products and servic...
03 Mar 2016 by Global Data USD $250 More Info
Dksh Holdings (Malaysia) Berhad (DKSH) - Financial and Strategic SWOT Analysis Review
SummaryDKSH Holdings (Malaysia) Berhad (DKSH) formerly Diethelm Holdings (Malaysia), a subsidiary of...
09 Jan 2016 by Global Data USD $300 More Info
Dksh Holdings (Malaysia) Berhad (DKSH) - Financial and Strategic SWOT Analysis Review
SummaryDKSH Holdings (Malaysia) Berhad (DKSH) formerly Diethelm Holdings (Malaysia), a subsidiary of...
08 Nov 2015 by Global Data USD $300 More Info
Healthcare Providers in Malaysia
SummaryHealthcare Providers in Malaysia industry profile provides top-line qualitative and quantitat...
15 Sep 2015 by Marketline USD $350 More Info

This report is published by Allied Market Research

Download Free Report Summary PDF

Malaysia Intravenous Immunoglobulin (IVIG) Market by Product Types (IgG, IgA, IgM, IgE and IgD), Application (Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy, Immunodeficiency Diseases, Myasthenia Gravis, Multifocal Motor Neuropathy, Primary Immune Thrombocytopenic Purpura, Inflammatory Myopathies, Specific Antibody Deficiency, Guillain-Barré Syndrome, Kawasaki Disease, [Report Updated: 24-05-2017] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...